shutterstock_306040325_edited_edited_edi

Company Information

Overview

Press Releases   

Events  

Company Information

        Profile

        Management Team

        IR Contacts

        FAQ

Stock Data     

 

Financial Filings    

 

Corporate Governance     

Annual Reports

Email Alerts

Profile

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a  diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.
 

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pipeline to address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), primary hypoparathyroidism and neurodegenerative diseases. Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2, the virus that causes COVID-19.